2022 World Conference on Lung Cancer (Posters)-P1.16-02. Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale

P1.16-02. Clinical Utility of ctDNA in Advanced NSCLC at Diagnosis or Where Insufficient Tissue Was Available, Based on the ESMO ESCAT Scale

Back to course

Pdf Summary

A study was conducted to assess the clinical utility of analyzing circulating tumor DNA (ctDNA) in patients with advanced non-small cell lung cancer (NSCLC). The study aimed to determine the rate of detection of genomic alterations (GAs) in ctDNA and evaluate their potential for guiding targeted therapies.<br /><br />The study included a total of 615 patients with advanced NSCLC, of whom 211 were treatment-naïve and 56 had insufficient tissue for traditional molecular profiling. Blood samples were collected at various time points, including at diagnosis, during therapy, and at progressive disease. The ctDNA was analyzed using next-generation sequencing.<br /><br />The results showed that 74% of patients had at least one ctDNA GA detected, with similar rates observed in the insufficient tissue cohort. The clinical utility for guiding targeted therapies in routine clinical practice was 21%, with 50% of patients having clinically informative GAs that may guide the use of investigational targeted therapies. The most common GAs detected in ctDNA were TP53 mutations, KRAS non-G12C mutations, EGFR sensitizing mutations, and KRAS G12C mutations.<br /><br />Furthermore, the study found that the objective response rate to targeted therapies was 50% in patients with tier 1 GAs and 89% in patients with tier 2 GAs. The study also highlighted the potential of liquid biopsy as a minimally invasive and easy alternative to tissue profiling for molecular analysis.<br /><br />In conclusion, the analysis of ctDNA using next-generation sequencing has clinical utility in identifying genomic alterations in patients with advanced NSCLC. These findings may guide treatment selection, including the use of targeted therapies, in routine clinical practice.

Asset Subtitle

Laura Mezquita, Spain

Meta Tag

Speaker Laura Mezquita, Spain

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

circulating tumor DNA

ctDNA

non-small cell lung cancer

NSCLC

genomic alterations

GAs

targeted therapies

next-generation sequencing

liquid biopsy

tissue profiling